source
- AbbVie’s etentamig shows strong survival and response gains in Phase 3 multiple myeloma trialAbbVie reported that its investigational bispecific T‑cell engager, etentamig, significantly reduced the risk of disease progression or death in a Phase 3 study of patients with relapsed or refract…
- Ionis secures FDA approval for zilganersen, a first treatment for Alexander diseaseIonis Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its antisense drug zilganersen for the treatment of Alexander disease, an ultra‑rare neurodegenerative disord…